Title:
SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2
Document Type and Number:
WIPO Patent Application WO/2022/215827
Kind Code:
A1
Abstract:
The present invention relates to a novel use of a Sanguisorba officinalis Linne extract in inhibiting the 3CL protease and RdRp activity of SARS-CoV-2 virus, and a composition of the present invention comprising the Sanguisorba officinalis Linne extract as an active ingredient has the effect of preventing or treating infection with SARS-CoV-2 virus or variants thereof by inhibiting the 3CL protease and RdRp activity.
Inventors:
CHANG MUN SEOG (KR)
LEE TAE HEE (KR)
LEE MIN JI (KR)
LEE SEUNG JAE (KR)
KIM HA YOUNG (KR)
MIN JUNG BIN (KR)
PARK JI HYE (KR)
CHOI WON HYUNG (KR)
PARK WOOK HA (KR)
LEE TAE HEE (KR)
LEE MIN JI (KR)
LEE SEUNG JAE (KR)
KIM HA YOUNG (KR)
MIN JUNG BIN (KR)
PARK JI HYE (KR)
CHOI WON HYUNG (KR)
PARK WOOK HA (KR)
Application Number:
PCT/KR2021/018706
Publication Date:
October 13, 2022
Filing Date:
December 10, 2021
Export Citation:
Assignee:
QGENETICS CO LTD (KR)
International Classes:
A61K36/739; A61P31/14
Foreign References:
| KR20160150177A | 2016-12-29 | |||
| US20110217753A1 | 2011-09-08 | |||
| CN103479758A | 2014-01-01 | |||
| KR101784254B1 | 2017-10-11 | |||
| KR20110117540A | 2011-10-27 |
Other References:
CHINSEMBU KAZHILA C.: "Coronaviruses and Nature’s Pharmacy for the Relief of Coronavirus Disease 2019", REVISTA BRASILEIRA DE FARMACOGNOSIA, vol. 30, no. 5, 1 October 2020 (2020-10-01), pages 603 - 621, XP055976319, DOI: 10.1007/s43450-020-00104-7
REMALI JUWAIRIAH, AIZAT WAN MOHD: "A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection", FRONTIERS IN PHARMACOLOGY, vol. 11, XP055976320, DOI: 10.3389/fphar.2020.589044
JACKSON CB ET AL.: "Mechanisms of SARS-CoV-2 entry into cells", NAT REV MOL CELL BIO, vol. 5, 2021, pages 1 - 18
HARVEY, W.T ET AL.: "SARS-CoV-2 variants, spike mutations and immune escape", NAT REV MICROBIOL, vol. 19, 2021, pages 409 - 424, XP037482862, DOI: 10.1038/s41579-021-00573-0
ANIRUDHAN V ET AL.: "Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19", J MED VIROL, vol. 93, no. 5, 2021, pages 2722 - 2734
ANIRUDHAN V ET AL.: "Targeting SARS-CoV -2 viral proteases as a therapeutic strategy to treat COVID-19", J MED VIROL, vol. 93, no. 5, 2021, pages 2722 - 2734
AFTAB, S.O ET AL.: "Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach", J TRANSL MED, vol. 18, 2020, pages 275
COX RM ET AL.: "Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets", NAT MICROBIO, vol. 6, no. 1, 2021, pages 11 - 18, XP037319215, DOI: 10.1038/s41564-020-00835-2
ROSENKE K ET AL.: "Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model", NAT COMMUN, vol. 12, no. 1, 2021, pages 2295
HUNG HC ET AL.: "Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid", J ANTIMICROB CHEMOTHE, vol. 65, no. 4, 2010, pages 676 - 83
GOVORKOVA EA ET AL.: "African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses", J VIROL, vol. 70, no. 8, 1996, pages 5519 - 5524, XP000909372
REMALI JUWAIRIAH, AIZAT WAN MOHD: "A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection", FRONTIERS IN PHARMACOLOGY, vol. 11, XP055976320, DOI: 10.3389/fphar.2020.589044
JACKSON CB ET AL.: "Mechanisms of SARS-CoV-2 entry into cells", NAT REV MOL CELL BIO, vol. 5, 2021, pages 1 - 18
HARVEY, W.T ET AL.: "SARS-CoV-2 variants, spike mutations and immune escape", NAT REV MICROBIOL, vol. 19, 2021, pages 409 - 424, XP037482862, DOI: 10.1038/s41579-021-00573-0
ANIRUDHAN V ET AL.: "Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19", J MED VIROL, vol. 93, no. 5, 2021, pages 2722 - 2734
ANIRUDHAN V ET AL.: "Targeting SARS-CoV -2 viral proteases as a therapeutic strategy to treat COVID-19", J MED VIROL, vol. 93, no. 5, 2021, pages 2722 - 2734
AFTAB, S.O ET AL.: "Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach", J TRANSL MED, vol. 18, 2020, pages 275
COX RM ET AL.: "Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets", NAT MICROBIO, vol. 6, no. 1, 2021, pages 11 - 18, XP037319215, DOI: 10.1038/s41564-020-00835-2
ROSENKE K ET AL.: "Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model", NAT COMMUN, vol. 12, no. 1, 2021, pages 2295
HUNG HC ET AL.: "Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid", J ANTIMICROB CHEMOTHE, vol. 65, no. 4, 2010, pages 676 - 83
GOVORKOVA EA ET AL.: "African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses", J VIROL, vol. 70, no. 8, 1996, pages 5519 - 5524, XP000909372
Attorney, Agent or Firm:
POLARIS INTERNATIONAL PATENT & LAW FIRM (KR)
Download PDF:
Previous Patent: POWER CABLE SYSTEM HAVING DIFFERENT-TYPE CONDUCTOR JUNCTION, AND POWER CABLE CONNECTION METHOD USING...
Next Patent: BRACE FOR PET
Next Patent: BRACE FOR PET